- Home
- DPG vs KROS Comparison
DPG vs KROS Comparison
Compare DPG & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DPG | KROS |
|---|---|---|
| Founded | 2011 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 482.1M | 565.0M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | DPG | KROS |
|---|---|---|
| Price | $12.72 | $21.53 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 15 |
| Target Price | N/A | ★ $22.20 |
| AVG Volume (30 Days) | 150.1K | ★ 1.2M |
| Earning Date | 01-01-0001 | 11-05-2025 |
| Dividend Yield | ★ 9.09% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.57 |
| Revenue | N/A | ★ $246,718,000.00 |
| Revenue This Year | N/A | $6,876.34 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $13.67 |
| Revenue Growth | N/A | ★ 37798.31 |
| 52 Week Low | $7.90 | $9.12 |
| 52 Week High | $13.58 | $72.37 |
Technical Indicators
Market Signals| Indicator | DPG | KROS |
|---|---|---|
| Relative Strength Index (RSI) | 38.76 | 76.91 |
| Support Level | $12.62 | $16.75 |
| Resistance Level | $13.03 | $22.55 |
| Average True Range (ATR) | 0.19 | 1.08 |
| MACD | -0.04 | 0.44 |
| Stochastic Oscillator | 15.57 | 82.21 |
Price Performance
Historical ComparisonAbout DPG Duff & Phelps Utility and Infrastructure Fund Inc.
Duff & Phelps Utility & Infrastructure Fund Inc. is an investment fund. Its investment objective is to seek total return, resulting from a high level of current income, with an emphasis on providing tax-advantaged dividend income.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.